X4 Pharmaceuticals reports progress on WHIM syndrome treatments

X4 Pharmaceuticals held a conference call on March 25, 2025, to discuss its financial performance for the fourth quarter and the full year of 2024. The call featured key executives, including CEO Dr. Paula Ragan and CFO Adam Mostafa. During the conference, Dr. Ragan highlighted that 2024 was a significant year for the company, especially for patients with WHIM syndrome, a rare immune disorder. The company is focused on developing new treatments and shared insights on upcoming regulatory and product development plans. Adam Mostafa, the CFO, addressed financial results and provided updates on the company's progress. He noted that they are optimistic about the future but cautioned that forward-looking statements come with risks and uncertainties. The call also included participation from other company leaders and investors who asked questions after the prepared remarks. The company plans to file a Form 10-K with the SEC, which will outline their financial performance in more detail.